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Abstract 
Background and purpose – Bridging therapy with low molecular weight heparin (LMWH) reportedly 
leads to a worse outcome for acute cardioembolic stroke patients due to a higher incidence of 
intracerebral bleeding. However, this practice is common in clinical settings.  
This observational study aimed to compare 1) the clinical profiles of patients receiving and not 
receiving bridging therapy; 2) overall group outcomes; 3) outcomes according to the type of 
anticoagulant prescribed. 
Methods – We analyzed data of patients from the prospective RAF and RAF NOACs studies. The 
primary outcome was defined as the composite of ischemic stroke, TIA, systemic embolism, 
symptomatic cerebral bleeding and major extra-cerebral bleeding observed at 90 days after the acute 
stroke. 
Results - Of 1,810 patients who initiated oral anticoagulant therapy, 371 (20%) underwent bridging 
therapy with full-dose LMWH. Older age and presence of leukoaraiosis were inversely correlated 
with the use of bridging therapy. Forty-two bridged patients (11.3%) reached the combined outcome 
vs 72 (5.0%) of the non-bridged patients (p = 0.0001). At multivariable analysis, bridging therapy 
was associated with the composite endpoint (OR 2.3; 95% CI 1.4-3.7, p < 0.0001), as well as ischemic 
(OR 2.2; 95% CI 1.3-3.9, p = 0.005) and hemorrhagic (OR=2.4; 95% CI 1.2-4.9, p = 0.01) endpoints 
separately.  
Conclusions – Our findings suggest that patients receiving LMWH have a higher risk of early 
ischemic recurrence and hemorrhagic transformation compared to non-bridged patients.  
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Introduction 
Oral anticoagulant therapy (OAC) is the treatment of choice for secondary prevention of stroke in 
patients with nonvalvular atrial fibrillation (NVAF). For this indication, the currently approved OACs 
are vitamin K antagonists (VKAs) and non-vitamin K antagonists oral anticoagulants (NOACs). 
VKAs are slower than NOACs in reaching the therapeutic anticoagulant effect, as their mechanism 
of action is the inhibition of vitamin-K dependent coagulation factors, which requires few days. The 
effect of VKAs is measured through the international normalized ratio (INR) that, as reflects the 
activity of VKA, requires few days to reach the therapeutic target. In some cases, a temporary therapy 
with full-dose low molecular weight heparin (LMWH) can be given alongside warfarin until the 
therapeutic INR level is achieved. Moreover, bridging therapy is used to counteract the transient 
prothrombotic effect in the initial phase of OAC treatment (1).  
The advantages of NOACs are their rapidity of action (2-3 hours for dabigatran, 2-4 hours for 
rivaroxaban, 3-4 hours for apixaban, 1-2 hours for edoxaban) and fast reversal, similar to heparin in 
that respect. Moreover, their standard dosages do not require titration, whereas VKAs do.  
Despite evidence that full-dose LMWH can be harmful in acute stroke care (2) in particular in the 
presence of atrial fibrillation (3), there are anecdotal reports of its use in selected patients (4, 5). 
Mostly, acute heparin treatment is used as bridging therapy until the therapeutic range of OACs is 
achieved, the so-called bridging therapy (1).  
By using data from the prospective RAF (6) and RAF-NOACs (7) studies, we aimed to evaluate 1) 
clinical profiles of patients who received or not bridging therapy; 2) differences in outcomes between 
these two groups and 3) differences in outcomes according to the type of OAC prescribed. 
 
Patients and methods 
We analyzed the data of patients from the prospective RAF and RAF NOACs studies that enrolled 
consecutive patients with acute ischemic stroke and NVAF. The methods and results of the RAF 
studies have been previously described in detail described in detail (6,7), and the data are available 
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from the corresponding author upon reasonable request. Both studies were approved by the local 
Institutional Review Board (IRB) if required. Patient exclusion criteria for both studies were: high 
risk of bleeding, defined as clinically significant liver disease (acute or chronic hepatitis, cirrhosis, or 
alanine aminotransferase level greater than three times the upper limit of normality), creatinine 
clearance (CrCl) <30 mL/min (for apixaban the threshold was 25 mL/min), life expectancy of <3–6 
months, the presence of uncontrolled hypertension (8), and the ongoing prescription of medications 
having known metabolic interactions with any type of OACs.  
A non-contrast cerebral computed tomography (CT) or cerebral magnetic resonance (MR) scan was 
performed on admission for each patient, to exclude for the presence of intracranial hemorrhage. 
Thrombolysis treatment was administered according to standard protocol, when appropriate. All of 
the participating centers provided Stroke Unit Care according to current international 
recommendations for acute ischemic stroke treatment (9-10). Stroke physicians were free to make 
decisions on the type of anticoagulant to be used for secondary prevention, as well as its starting time. 
NVAF was classified as paroxysmal (episodes terminating spontaneously within 7 days), persistent 
(episodes lasting more than 7 days requiring pharmacologic and/or electrical stimulation), or 
permanent (persisting for more than 1 year, either because cardioversion failed or had not been 
attempted) (11).  
A second brain CT scan or MR was performed 24-72h from stroke onset for all patients. Hemorrhagic 
transformation (HT) was defined on CT scan as any degree of hyperdensity within the area of low 
attenuation and was classified as either hemorrhagic infarction (HI) or parenchymal hematoma (PH) 
(12, 13). On MRI, HT was defined as hypointensity on axial T1-weighted (T1W) or T2-weighted 
(T2W) images. HT was considered to be symptomatic if it was associated with an increase of 4 points 
or more in the NIHSS score and there was no evidence of intracranial bleeding on the first CT (14). 
The sites and sizes of the qualifying infarcts were determined based on standard templates (15, 16) 
as: 1) small, when a lesion was ≤1.5 cm in the anterior or posterior circulation; 2) medium, when a 
lesion was in a superficial cortical branch of middle cerebral artery (MCA), in the MCA deep branch, 
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in the internal border zone territories, in a cortical superficial branch of posterior cerebral artery 
(PCA), in a cortical superficial branch of the anterior cerebral artery (ACA); 3) large anterior, when 
a lesion involved the complete territory of MCA, PCA, or ACA, in 2 superficial cortical branches of 
MCA, in a cortical superficial branch of MCA associated to the MCA deep branch, or in more than 
1 artery territory (e.g. MCA associated to ACA territories); 4) large posterior, when a lesion was ≥1.5 
cm in the brain stem or cerebellum (13). 
For the purpose of this analysis, bridging therapy was defined as any temporary full-dose of LMWH 
(e.g. 100 UI/Kg of enoxaparin twice a day) started together before or with VKAs, in order to cover 
the time needed by the latter to reach the therapeutic effect (1) or as any full-dose (given for at least 
24 hours) of LMWH prior to the use of a NOAC. 
 
Risk factors 
Data on stroke risk factors were collected as previously described (6,7): age, sex, history of 
hypertension (blood pressure of ≥140/90 mm Hg at least twice before stroke or already under 
treatment with antihypertensive drugs), history of diabetes mellitus (fasting serum glucose level ≥126 
mg/dL preprandial on 2 examinations, glucose level ≥200 mg/dL postprandial, or HbA1c≥6.5%, or 
under antidiabetic treatment), current cigarette smoking, past smoking (cessation less than 5 years 
ago), hyperlipidemia (total cholesterol ≥200 mg/dL or triglyceride ≥140 mg/dL or already under lipid 
lowering therapy), history of symptomatic ischemic heart disease (myocardial infarction, history of 
angina or existence of multiple lesions on thallium heart isotope scan or evidence of coronary disease 
on coronary angiography), history of symptomatic peripheral arterial disease (intermittent 
claudication of presumed atherosclerotic origin; or ankle/arm systolic blood pressure ratio <0.85 in 
either leg at rest; or history of intermittent claudication with previous leg amputation, reconstructive 
surgery, or angioplasty), alcohol abuse (≥300 g per week), obesity (body mass index ≥30 kg/m2), or 
previous stroke/TIA). White matter changes (leukoaraiosis) defined on the first CT (or MRI) 
examination as ill-defined and moderately hypodense (or hyperintensity on T2-weighted on MRI) 
 
9 
areas of ≥5 mm according to published criteria were investigated (17). Leukoaraiosis in the deep 
white matter was dichotomized into absent versus mild, moderate, or severe. Other baseline variables 
obtained at admission for all patients included: fasting serum glucose, fasting serum cholesterol (total, 
HDL, and LDL), platelet count, international normalized ratios (INR), activated partial 
thromboplastin time (aPTT), systolic blood pressure, and diastolic blood pressure. 
Data on the use of any antiplatelet, anticoagulants or thrombolytic agent, before admission, at baseline 
and during the follow-up period, were recorded. 
The CHA2DS2-VASc score was calculated before and after the index event (18). 
 
Evaluation of Outcomes 
Patients were followed-up prospectively through face-to-face or telephone interviews. Study 
outcomes at 90 days were: 1) recurrent ischemic cerebrovascular events (stroke or TIA) and/or 
symptomatic systemic embolisms; 2) symptomatic cerebral bleedings and/or major extra-cerebral 
bleedings. 
The primary study outcome was the composite of stroke, TIA, systemic embolism, symptomatic 
cerebral bleeding and major extra-cerebral bleeding (6,7). HTs found on neuroimaging 24-72 hours 
after onset were not considered outcome events unless classified as symptomatic.  
Stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin in a site 
consistent with the territory of a major cerebral artery and categorized as ischemic or hemorrhagic. 
TIA was defined as a transient episode of neurological dysfunction caused by focal brain ischemia 
without acute infarction. Systemic embolism was defined as an acute vascular occlusion of an 
extremity or organ confirmed by imaging, surgery, or autopsy. Cerebral bleeding was considered 
symptomatic if associated with a decline in neurological status (an increase of 4 points or more in the 
NIHSS score or leading to death). Major extra-cerebral bleeding was defined as a reduction in the 
hemoglobin level of at least 2 g per deciliter, requiring blood transfusion of at least 2 units, or 
symptomatic bleeding in a critical area or organ (19).  
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Disability and mortality at 90 days were also assessed using the modified Rankin Scale (mRS). Non-
disabling functional outcome was defined as an mRS score of 0-2. 
 
Statistical analysis 
Differences in patient characteristics between the two groups (bridging vs non-bridging therapy) were 
assessed utilizing the Chi-square test. Univariable analysis was performed to compare clinical 
features at admission and their risk factors. The two continuous variables, NIHSS score and age, are 
reported as mean values and standard deviations (SD). Whereas, categorical variables are reported as 
percentages.   
Multivariable logistic regression was performed to investigate independent variables and their 
possible correlations with the bridging therapy. The variables included in the model were: NIHSS 
score, the presence of diabetes mellitus, arterial hypertension, dyslipidemia, paroxysmal AF, 
pacemaker; lesion size, leukoaraiosis, CHA2DS2VASc score after the event, as well as the histories 
of previous stroke or TIA, current smoking habit, congestive heart failure and/or myocardial 
infarction. 
Univariable analysis was used to compare the combined outcomes of the two groups, for recurrence 
of ischemic stroke and occurrence of bleeding. The same analysis was performed to compare the 
combined outcomes of the two OAC regimens.  
Given the difference of numbers of patients in the two groups, and the possible presence of 
confounding factors influencing outcomes, a propensity score (PS) matching was also performed, and 
outcomes were evaluated in the two groups, each of 323 patients, obtained after matching (20); the 
PS is the probability that a patient would have been treated with bridging therapy with LMWH given 
his pretreatment variables. Equal PS values guarantee equal distribution of measured pretreatment 
variables at baseline on the sample level; thus, PS is an attempt to create homogeneous groups for 
comparison when data from a randomization procedure are not available. The individual propensity 
scores for analyzing bridging and non-bridging therapy groups were estimated with a logit model 
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including the following variables: age, sex, NIHSS at admission, vascular risk factors, lesion size, 
use of NOACs and CHA2DS2Vasc. To estimate treatment effects, Cox proportional hazards models 
were performed on the entire cohort to derive crude and PS-adjusted Hazard Ratios (HRs). 
The observed correlation between the combined outcome (survival) and the set of variables was 
analyzed using the proportional Cox model; here all the variables included in our multivariable 
analysis were used. Patients were censored at the time of an outcome event, death or lost during 
follow-up. 
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Results 
A total of 2,164 patients were enrolled in the RAF (n = 1,037) and RAF NOACs (n = 1,127) studies. 
Patients who did not start any anticoagulation were excluded, as well as those who were treated only 
with LMWH. This resulted in 1,821 patients, of whom another 11 were excluded due to incomplete 
data related to the administration of OAC therapy. A further 30 patients were lost during follow-up. 
After index acute ischemic stroke, 371/1,810 patients (20.49%) underwent bridging therapy with 
LMWH (Figure I of Supplemental Material). 
OAC was initiated with warfarin in 561/1,780 patients (31.52%) and NOACs were started in 
1,219/1,780 (68.48%). The median for initiating bridging therapy was 7 days (Inter Quartile Range - 
IQR 11), while for the non-bridging group this number was a median of 8 days (IQR 14). Mean 
NIHSS at admission was 7.2±6.3 in the bridging group and 7.7±6.2 in the non-bridging group (p = 
ns). 
 
Clinical characteristics of the bridging and non-bridging groups 
The bridging and non-bridging groups differed for age, sex, the percentage of medium-sized lesions, 
of large anterior circulation lesions, and for the presence of leukoaraiosis (Table 1). The mean ages 
were 73.0±9.7 years vs 76.1±9.4 years, respectively (p<0.001). Of the 371 bridging patients, 197 
(53.1%) were male, while 663 (46.1%) in the non-bridging group (p=0.017). In the bridging group, 
153 patients (41.2%) had medium-sized lesions vs 469 (32.6%) in the non-bridging group (p=0.010); 
large anterior lesions were present in 41 (11.1%) of bridging patients and 232 (16.1%) non-bridging 
patients (p=0.006). Leukoaraiosis was diagnosed in 143 (38.5%) and 786 (54.6%) patients, 
respectively (p=0.001). 
41/371 (11.0%) in the bridging group were simultaneously taking an antiplatelet agent (either aspirin 
100 mg per day or clopidogrel 75 mg per day), while in the non-bridging group patients under 
antiplatelet therapy were 200/1,439 (13.9%), being statistically similar (p = 0.2). 
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At multivariable analysis, age (OR 0.97; 95% CI 0.95-0.98, p = 0.001) and leukoaraiosis (OR 0.60, 
95% CI 0.47-0.78, p = 0.001) were inversely correlated with the use of bridging therapy (Table I of 
Supplemental Material).  
 
Outcomes in the bridging and non-bridging groups   
Overall, 42/371 bridging patients (11.3%) experienced the combined outcome, compared to 72/1,409 
in the non-bridged group (5.1%) (p = 0.0001). Within the bridging group, 29/42 (69%, 7.8% of all 
outcomes) versus 44/72 (61.11%, 3.1% of all outcomes) in the non-bridging group had an ischemic 
stroke, respectively. Major bleedings occurred in 19/42 patients (45.23%, 5.1% of all outcomes) in 
the bridging group and 32/72 (44.44%, 2.3% of all outcomes) in the non-bridging group (p=0.08) 
(Table 2). 
In the multivariable analysis, bridging therapy was associated with combined outcome (OR 2.3; 95% 
CI 1.4-3.7, p < 0.0001), ischemic event (OR 2.2; 95% CI 1.3-3.9, p = 0.005) and hemorrhagic event 
(OR 2.4; 95% CI 1.2-4.9, p = 0.01) (Table 3).  
Propensity score matching was performed on 323 patients in each group. The two groups were 
comparable for age (74.3±8.7 years in the non-bridging group vs. 74.0±8.5 years in the bridging 
group, p 0.7), sex (170 males, 52.6% of the total, in the non-bridging group vs. 161 males, 49.8% of 
the total, in the bridging group, p 0.5), NIHSS at admission (7.5±6.3 vs. 7.6±6.3); also, they were 
comparable for clinical characteristics; NOACs were used as anticoagulants in 114 patients (35.3%) 
in the non-bridging group vs 115 patients (35.6%) in the bridging group (p = 1.0) (Table II of 
Supplemental Material). 
The Propensity score analysis confirmed the results of the multivariable analysis; bridging therapy 
was associated with combined outcome (HR 3.08; 95% CI 1.68-5.64, p < 0.001), ischemic event (HR 
4.50; 95% CI 1.88-10.75, p < 0.003) and hemorrhagic event (HR 2.71; 95% CI 1.16-6.37, p = 0.017) 
(Table 4); the same results were confirmed after the PS was adjusted for age, sex, NIHSS at 
admission, vascular risk factors, lesion size and CHA2DS2Vasc: combined outcome had a HR 2.23 
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(95% CI 1.41-3.52, p < 0.001), ischemic event a HR 2.23 (95% CI 1.29-3.88, p < 0.003) and 
hemorrhagic event a HR 2.24 (95% CI 1.15-4.36, p = 0.017) (Table 4). 
In Figure II of the Supplemental Material the cumulative hazard rates for the combined outcome, in 
respect to treatment group, according to the Cox regression model (HR 0.95; 95% CI 0.60-1.49; p = 
0.8) are reported. 
  
Outcomes according to the type of OAC used in the bridging and non-bridging groups 
Out of the 1,780 included patients, 1,219 were treated with NOACs and 561 with VKAs. The 
combined outcome was observed in 62 (5.1%) and 52 (9.3%) patients, respectively (p = 0.01). An 
ischemic outcome was observed in 35 (2.9%) and 38 (6.8%) of the patients treated with NOACs of 
VKA, respectively (p = 0.0001). The NOACs and VKAs groups did not differ concerning the 
hemorrhagic events that were 29 (2.4%) and 22 (3.9%), respectively. 
In the bridging group, 120 patients were treated with NOACs and 251 with VKAs; in the non-bridging 
group, 1,099 patients were treated with NOACs and 310 with VKAs. Within each group, no 
statistically significant differences were observed in either the combined outcome or the hemorrhagic 
event rate according to the type of OAC used. However, a statistically significant difference was 
observed for the rate of ischemic events in the non-bridging group: 27 events (2.5%) in patients 
treated with NOACs vs 17 events (5.5%) in patients treated with VKAs (p = 0.015). 
When stratifying each group according to the type of OAC, no statistically significant differences 
were observed between and within each group in outcome rates. 
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Discussion 
This combined analysis of the RAF and RAF NOACs data suggested that bridging therapy was 
associated with overall higher risks of early ischemic recurrence and symptomatic intracranial 
bleeding; independently of the type of OACs administered. The latter finding is in line with that 
reported by IST, where an increase in hemorrhagic stroke was reported (1.2% for heparin vs 0.4% for 
aspirin).  Data from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation 
(ORBIT-AF) registry on bridging reported a higher incidence of myocardial infarction, stroke or 
systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly 
higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001) (21). 
Bridging therapy with heparin is sometimes started in subacute ischemic stroke, as it is thought to 
reduce the risk of ischemic recurrence due to a possible prothrombotic activity of warfarin at 
treatment initiation (22). However, reliable data on warfarin’s role in blocking endogenous 
anticoagulants has yet to be proven. It is plausible that warfarin alone might be more effective than 
bridging therapy with warfarin in the sub-acute phase of AF-associated stroke.   
Another possible explanation of the increased ischemic stroke risk of heparin may be its under-dosing 
as patient body weights are generally based on estimation.  Moreover, our study did not allow to 
distinguish between ischemic recurrence in a different vascular territory from the index stroke, and 
recurrence in the same vascular territory, that may have been a progression of the first ischemia. (23). 
In our study, bridging therapy with NOACs was also associated with a higher rate of ischemic events 
compared to those receiving NOACs alone. Besides RAF-NOAC, there are only a few prospective 
data available from observational studies on the safety and efficacy of early secondary prevention 
using NOACs after cardioembolic stroke. Of these, the SAMURAI-NVAF study reported that no 
ICH was recorded after a NOAC-initiation within a median of four days post stroke (24). Whereas, 
another observational study reported no significant difference in the rate of recurrent ischemic events 
when comparing early NOAC treatment within 7 days and after 7 days (25). Ongoing studies such as 
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the “TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation” (26) 
and The “Early Versus Late Initiation of Direct Oral Anticoagulants in Post-Ischaemic Stroke Patients 
with Atrial fibrillation study (ELAN; 27) are designed to estimate the benefit of early versus late 
initiation of NOACs in patients with acute ischemic stroke related to AF without bridging therapy. 
Regarding the use of antiplatelets prior to initiating oral anticoagulation, 11.0% of bridging and 13.9% 
of non-bridging patients had been prescribed aspirin or clopidogrel. Therefore, it does not seem 
plausible that the associations would significantly increase bleeding risks in patients treated with 
LMWH. 
When comparing bridging versus non-bridging outcomes associated with OAC type, the risk profile 
associated with bridging appeared similar between NOACs and VKAs, therein suggesting that 
bridging therapy should be avoided particularly in patients who will be treated with NOACs in 
secondary prevention (see Cox regression survival curve, Figure II of Supplemental Material). 
An analysis of the patient profiles indicated that older patients (mean age 76.1 vs 73.0 years), those 
with leukoaraiosis and/or with large anterior circulation lesions were less likely to receive bridging 
therapy. This might reflect a routine use of LMWH in only selected cases, since leukoaraiosis and 
large infarct volume are clinical predictors of both symptomatic and asymptomatic HT (28-30), both 
spontaneous (28) and after thrombolytic therapy (31). 
However based on our study results, there seems to be still overuse of LMWH due to a non-adherence 
to current guidelines. This overuse may also be due to the slower reversal of VKA and to the absence, 
at the time of enrollment of the RAF and RAF NOACs, of an antidote for NOACs in case of bleeding 
(32). Regarding the choice of patients to be treated with bridging therapy, there could have been a 
selection bias. Moreover, unrecorded factor that can sway clinician decisions on the use of bridging 
therapy may include dysphagia in acute stroke phase, preferring subcutaneous to oral administrations. 
A limitation of this analysis was that it was non-randomized, so it is possible that some confounding 
factors might have influenced the outcome results. We did not have information on the exact time 
when INR reached the target level in warfarin-treated patients. Moreover, the sizes of the two groups 
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were not equally represented, since only 20.5% of patients underwent bridging therapy with LMWH. 
Moreover, we are unable to specify the types of bleedings, as the RAF and RAF NOACs studies were 
not designed to collect such data. 
 
In conclusion, our study suggests that the use of full-dose LMWH preceding oral anticoagulation in 
atrial fibrillation patients hospitalized for a recent ischemic stroke was associated with a higher risk 
of early ischemic recurrence and hemorrhagic events. 
 
Aknowledgements: 
The Authors thank ARS Umbria for its unrestricted support. 
 
Disclosures:  
V. Caso: honoraria as a member of the speaker bureau and as consultant or advisory board of 
Boehringer Ingelheim, Bayer, Daichii-Sankyo, Pfizer, Ever Pharma. All honoraria were paid to 
ARS UMBRIA.  
G. Agnelli: honoraria as a member of the speaker bureau of Boehringer Ingelheim and Bayer. 
C. Becattini: honoraria as a member of the speaker bureau of Bristol Meyer Squibb and Bayer.  
J. Putaala: honoraria for lectures related to atrial fibrillation and anticoagulants for Orion Pharma, 
Bristol Meyer Squibb, Pfizer, Bayer, and Boehringer Ingelheim.  
T. Tatlisumak: Member of the Steering Committee of the NAVIGATE ESUS trial. Advisory board 
membership: Bayer, Sanofi Aventis, Lumosa, Boehringer Ingelheim, Pfizer. Research contracts 
with Boehringer Ingelheim, Bayer, Portola, Pfizer, Sanofi Aventis, BrainsGate. 
G. Ntaios: member of the Steering Committee of the NAVIGATE ESUS trial. Speaker 
fees/Advisory Boards/Research support from Amgen; Bayer; BMS/Pfizer; Boehringer Ingelheim; 
Elpen; European Union; Galenica; Sanofi; Winmedica. No fees are directly received personally. 
 
18 
W. Ageno: speaker’s honoraria from, and participated in scientific advisory boards for Boehringer 
Ingelheim, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo; research support from Bayer and 
Boehringer Ingelheim. 
D. Toni: honoraria as a member of speaker bureau and as advisory board of Boehringer Ingelheim, 
Pfizer, Bristol-Myers Squibb and Bayer. 
P. Michel: Research Grant by Swiss National Science Foundation and Swiss Heart Foundation; 
speaker fees by Bayer, Boehringer Ingelheim, Covidien, St. Jude Medical; honoraria as advisory 
relationship by Pierre-Fabre, Bayer, Bristol Meyer Squibb, Amgen, and Boehringer Ingelheim.  
P. Vanacker: honoraria as a member of speaker bureau of Daiichi-Sankyo and as advisory board of 
Boehringer Ingelheim. 
M. Paciaroni: honoraria as a member of the speaker bureau of Aspen, Sanofi-Aventis, Boehringer 
Ingelheim, Bayer, Bristol Meyer Squibb, Daiichi Sankyo, Medtronic and Pfizer.  
The other authors have nothing to disclose. 
 
  
 
19 
 
References 
1. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. 
Perioperative management of antithrombotic therapy: Antithrombotic Therapy and 
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based 
Clinical Practice Guidelines. Chest. 2012;141:e326S-e350S. 
2. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in 
acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke. 
2007;38:423-30. 
3. Whiteley WN, Adams HP Jr, Bath PM, Berge E, Sandset PM, et al. Targeted use of heparin, 
heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic 
stroke: an individual patient data meta-analysis of randomised controlled trials. Lancet 
Neurol. 2013;12:539-45. 
4. Al-Sadat A, Sunbulli M, Chaturvedi S. Use of intravenous heparin by North American 
neurologists. Stroke 2002;33:1574–77. 
5. Caplan LR. Resolved: heparin may be useful in selected patients with brain ischemia. Stroke 
2003;34:230–31. 
6. Paciaroni M, Agnelli G, Falocci N, Caso V, Becattini C, Marcheselli S, et al. Early Recurrence 
and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect 
of Anticoagulation and Its Timing: The RAF Study. Stroke. 2015;46:2175-82. 
7. Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C, et al. Early 
Recurrence and Major Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation 
Treated With Non-Vitamin-K Oral Anticoagulants (RAF-NOACs) Study. J Am Heart Assoc. 
2017;6:e0007034.  
8. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 
Evidence-based guideline for the management of high blood pressure in adults: report from 
 
20 
the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 
2014;311:507-20. 
9. European Stroke Organisation (ESO) Executive Committee. Guidelines for management of 
ischemic stroke and transient ischemic attack. Cerebrovasc Dis. 2008;25:457–507.   
10. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. 
American Heart Association Stroke Council. 2018 Guidelines for the Early Management of 
Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the 
American Heart Association/American Stroke Association. Stroke. 2018;49:e46-e110. 
11. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. American 
College of Cardiology/American Heart Association Task Force on Practice Guidelines; 
European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm 
Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management 
of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American 
Heart Association Task Force on Practice Guidelines and the European Society of Cardiology 
Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the 
Management of Patients With Atrial Fibrillation): developed in collaboration with the 
European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 
2006;114:e257-354. Erratum in: Circulation. 2007;116:e138.  
12. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, Del Zoppo GJ; for the rtPA 
Acute Stroke Study Group. Neuroradiologic evaluation of patients with acute stroke treated 
with rtPA. AJNR Am J Neuroradiol. 1993;14:3–13.   
13. Paciaroni M, Agnelli G, Corea F, Ageno W, Alberti A, Lanari A, et al. Early hemorrhagic 
transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: 
results of a prospective multicenter study. Stroke. 2008;39:2249–2256.   
 
21 
14. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. ECASS 
Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl 
J Med. 2008;359:1317–1329.   
15. Tatu L, Moulin T, Bogousslavsky J, Duvemoy H. Arterial territories of the human brain: 
cerebral hemispheres. Neurology. 1998;50:1699–1708.   
16. Tatu L, Moulin T, Bogousslavsky J, Duvemoy H. Arterial territories of the human brain: 
brainstem and cerebellum. Neurology. 1996;47:1125–1135.  
17. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin A, Sjogren M, et al. A new rating 
scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32:1318–
1322.  
18. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for 
predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based 
approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263–272.  
19. Schulman S, Kearon C. Definition of major bleeding in clinical investigations and anti-
hemostatic medical products in non-surgical patients. J Thromb Haemost. 2005;3:692–694.  
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies 
for causal effects, Biometrika. 1983;70:41–55. 
21. Steinberg BA, Peterson ED, Kim S, Thomas L, Gersh BJ, Fonarow GC, et al. Outcomes 
Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use 
and outcomes associated with bridging during anticoagulation interruptions in patients with 
atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131:488-94. 
22. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse 
effects. J Clin Pharmacol. 1992;32:196-209. 
23. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus 
aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind 
 
22 
randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 
2000;355:1205-10. 
24. Toyoda K, Arihiro S, Todo K, Yamagami H, Kimura K, Furui E, et al. SAMURAI Study 
Investigators. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular 
atrial fibrillation in Japan: the SAMURAI-NVAF study. Int J Stroke. 2015;10:836-42. 
25. Seiffge DJ, Traenka C, Polymeris A, Hert L, Peters N, Lyrer P, et al. Early start of DOAC 
after ischemic stroke: Risk of intracranial hemorrhage and recurrent events. Neurology. 
2016;87:1856-1862. 
26. Oldgren J, Åsberg S. Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With 
Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized 
Controlled Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT02961348. Last accessed 
January 30, 2019.  
27. Fischer U. Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke 
Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised - 
controlled, Two-arm, Assessor-blinded Trial. 
https://clinicaltrials.gov/ct2/show/NCT03148457. Last accessed January 30, 2019.  
28. Tan S, Wang D, Liu M, Zhang S, Wu B, Liu B. Frequency and predictors of spontaneous 
hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol. 
2014;261:905–12.  
29. Kalinin MN, Khasanova DR, Ibatullin MM. The hemorrhagic transformation index score: a 
prediction tool in middle cerebral artery ischemic stroke. BMC Neurol. BioMed Central; 
2017;17:177. 
30. Fierini F, Poggesi A, Pantoni L. Leukoaraiosis as an outcome predictor in the acute and 
subacute phases of stroke. Expert Rev Neurother. 2017;17:963-975.  
 
23 
31. Liu Y, Zhang M, Chen Y, Gao P, Yun W, Zhou X. The degree of leukoaraiosis predicts 
clinical outcomes and prognosis in patients with middle cerebral artery occlusion after 
intravenous thrombolysis. Brain Res. 2018;1681:28-33. 
32. Husted S, Verheugt FW, Comuth WJ. Reversal Strategies for NOACs: State of Development, 
Possible Clinical Applications and Future Perspectives. Drug Saf. 2016;39:5-13. 
  
 
24 
 
Tables:  
 
 
Table 1: Clinical characteristics of study patients (n=1810). NIHSS = National Institute of Health 
Stroke Scale; AF = Atrial fibrillation; CHF = Congestive Heart Failure; MI = Myocardial 
Infarction; PAD = peripheral artery disease; PMK = pacemaker; HT = hemorrhagic 
transformation. 
 
 
Clinical characteristics of patients (n = 1810) 
  Bridging therapy Non-bridging 
therapy 
p value 
  (n = 371) (n = 1439)   
Age (years) 73.0±9.7 76.1±9.4 0.0001 
Male sex 197 (53.1%) 663 (46.1%) 0.017 
NIHSS at admission 7.2±6.3 7.7±6.2 n.s. 
Diabetes mellitus 80 (21.6%) 297 (20.6%) n.s. 
Hypertension 275 (74.1%) 1124(78.1%) n.s. 
Dyslipidemia 118 (31.8%) 510 (35.4%) n.s. 
Paroxysmal AF 153 (41.2%) 656 (45.6%) n.s. 
Smoking habit 46 (12.4%) 140 (9.7%) n.s. 
History of Stroke/TIA 84 (22.6%) 382 (26.5%) n.s. 
History of CHF 74 (19.9%) 232(16.0%) n.s. 
History of MI 48 (12.9%) 183 (12.7%) n.s. 
History of PAD 40 (10.8%) 116 (8.1%) n.s. 
PMK 21 (5.7%) 93 (6.5%) n.s. 
HT 24-72 hrs 40 (10.8%) 135 (9.4%) n.s. 
CHA2DS2-VASc after >4 255 (68.7%) 1094 (76.0%) p = 0.03 
Antiplatelet therapy 41 (11.0%) 200 (13.9%) n.s. 
Cerebral Infarct Pattern        
Small  153 (41.2%) 582 (40.4%) n.s. 
Medium 153 (41.2%) 469 (32.6%) 0.010 
Large anterior circulation  41 (11.1%) 232 (16.1%) 0.006 
Large posterior circulation  15 (4.0%) 92 (6.4%) n.s. 
Leukoaraiosis 143 (38.5%) 786 (54.6%) 0.0001 
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Univariable analysis (n = 1780) 
  Bridging therapy 
(n = 371) 
Non-bridging therapy 
(n = 1409) 
p value 
Combined outcome 42 (11.3%) 72 (5.1%) 0.0001 
Ischemic outcome 29 (7.8%) 44 (3.1%) 0.0001 
Hemorrhagic outcome 19 (5.1%) 32 (2.3%) 0.008 
 
Table 2: univariable analysis; differences in outcomes at 90 days between patients treated with 
bridging with LMWH and those without bridging therapy. 
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Logistic Regression Analysis  
  OR (95% CI) p 
Bridging therapy (combined outcome) 2.3 (1.4 - 3.7) <0.0001 
Bridging therapy (ischemic outcome) 2.2 (1.3 - 3.9) 0.005 
Bridging therapy (hemorrhagic outcome) 2.4 (1.2 – 4.9) 0.01 
 
Table 3: Multivariable analysis adjusted for NIHSS score, diabetes mellitus, arterial 
hypertension, dyslipidemia, paroxysmal AF, pacemaker; lesion size, leukoaraiosis, 
CHA2DS2VASc score after the event, history of previous stroke or TIA, type of oral anticoagulant 
(VKA vs. NOAC), current smoking, congestive heart failure and/or myocardial infarction; 
differences in outcomes at 90 days between patients treated with bridging with LMWH and those 
without bridging therapy. 
  
 
27 
 
Propensity score matching: outcomes 
  no bridging 
therapy 
(n = 323) 
bridging therapy 
(n = 323) 
HR (95% CI) P value 
combined outcome 13 (4.0%) 40 (12.3%) Unadjusted 3.08 (95% CI 1.68-5.64) 
Adjusted      2.23 (95% CI 1.41-3.52) 
0.0001 
ischemic outcome 6 (1.9%) 27 (8.3%) Unadjusted 4.50 (95% CI 1.88-10.75) 
Adjusted      2.23 (95% CI 1.29-3.88) 
0.003 
 
hemorrhagic outcome 7 (2.2%) 19 (5.9%) Unadjusted 2.71 (95% CI 1.16-6.37) 
Adjusted      2.24 (95% CI 1.15-4.36) 
0.017 
 
Table 4: Propensity score matching: outcomes 
 
